Cagrilintide used for the treatment of obesity and type 2 diabetes Once weekly mazdutide, a glucagon like peptide 1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY 1 trial results: https: nej.md 4koUvaP Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY 2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the Mazdutide (IBI362): The Next Generation Dual GLP 1 Glucagon Agonist for Obesity and Metabolic Health